"Twenty drug approvals in the United States this year, and others in the next few years, will help replace the revenue"
They make that statement at the end of the article in an almost offhand way, but no analysis I have seen for any of the big pharmas shows them anywhere near to replacing lost revenue from the near-term patent expirations. We are in a period of the fewest approvals for new drugs than almost any time since the beginning of the FDA (and similar regulatory agencies around the world). The industry is in bad shape, and there seems to be no relief for the lack of R&D productivity any time soon.
Comments
"Twenty drug approvals in the United States this year, and others in the next few years, will help replace the revenue"
They make that statement at the end of the article in an almost offhand way, but no analysis I have seen for any of the big pharmas shows them anywhere near to replacing lost revenue from the near-term patent expirations. We are in a period of the fewest approvals for new drugs than almost any time since the beginning of the FDA (and similar regulatory agencies around the world). The industry is in bad shape, and there seems to be no relief for the lack of R&D productivity any time soon.